Anatara Lifesciences Ltd

A$0.01As of Sun 8 Nov 2026, 12:00 UTC

ASX:ANRHealthcare

Country Australia

PE (Fwd) •••

TSR 10Y CAGR (39.26%)

Div yield —

ROE (149.62%)

Biotechnology

Beta (5Y) 0.67

PE TTM —

TSR TTM (38.46%)

Mkt cap A$2.528M

ROIC (70.63%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$0.0081

1.05%

70.01%

Hold 6|5|11|8|11

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.045

Revenue$M

0.572

0.569

0.559

0.559

0.565

0.575

0.569

0.574

0.582

0.571

0.050

0.19%

(0.15%)

32

4.48

Revenue growth%

8.04

8.02

9.42

6.76

6.77

3.95

6.50

6.68

4.59

1.91

7.49

4.59

6.72

43

8.07

Gross margin%

3.29

1.18

0.40

0.40

0.40

0.97

3.27

2.93

2.06

3.49

22.67

2.93

1.62

87

20.53

Operating margin%

10.97

11.50

10.50

9.74

9.67

7.16

5.33

8.17

8.98

11.46

6.93

8.17

9.71

12

12.90

Net margin%

4.25

1.43

0.40

1.51

1.32

3.85

5.05

5.95

5.23

7.68

5.63

5.23

4.05

25

22.23

P/E ratio (avg)x

15.80

14.02

12.91

12.33

13.24

13.40

13.08

13.06

13.54

13.04

35.92

13.08

13.16

23

9.738

EV/EBITx

14.98

15.75

17.17

19.56

20.57

23.68

23.21

24.50

26.84

30.24

17.70

24.50

21.89

70

24.32

FCF yield (avg)%

9.51

10.83

13.56

11.73

9.72

9.74

11.55

12.26

10.28

11.40

10.91

11.40

11.11

68

7.04

FCF margin%

20.19

21.63

20.29

18.66

19.34

17.61

15.28

12.88

14.73

13.84

5.13

14.73

18.13

13

0.464

FCF / Net incomex

1.615

1.651

1.686

1.696

1.438

1.358

1.301

1.125

1.124

1.218

0.558

1.218

1.398

51

22.86

ROIC%

0.40

3.07

2.89

4.80

3.55

4.19

2.87

1.36

2.49

4.27

15.12

2.87

2.98

72

22.73

Return on equity%

13.66

15.31

12.95

15.70

14.44

17.20

16.90

17.20

16.51

15.59

4.97

16.90

15.65

12

11.86

Return on assets%

17.20

16.08

18.50

18.49

16.92

17.20

14.25

15.08

15.35

16.52

18.43

15.35

16.72

21

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

11.25%

8.89%

—

20.70

EPS growth%

0.40

0.40

0.94

3.54

5.23

2.41

3.64

6.64

8.68

6.74

21.58

6.64

3.59

76

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

(5.98%)

(6.22%)

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

4.43%

4.34%

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

(4.40%)

(5.05%)

—

17.70

Div yield (avg)%

7.16

6.20

8.80

9.47

10.59

10.02

8.71

9.75

7.90

10.51

2.80

9.75

9.13

57

11.90

Payout ratio%

8.74

7.86

8.43

6.92

7.53

9.31

7.04

7.81

10.58

9.26

26.86

9.26

8.15

54

312.2

Shares (diluted)M

401.6

397.5

435.3

434.8

504.6

597.0

670.3

765.3

827.8

949.8

315.1

13.48%

10.36%

7

24.68

Buyback yield%

28.18

30.08

28.57

26.35

23.60

25.49

27.96

25.05

25.72

25.32

12.99

25.49

26.04

15

0.510

D/E ratiox

0.999

1.158

1.198

1.357

1.429

1.484

1.537

1.700

1.897

1.883

0.656

1.700

1.456

89

0.081

Enterprise value$M

0.440

0.414

0.441

0.472

0.491

0.474

0.484

0.486

0.440

0.448

0.616

(1.80%)

(0.65%)

35

0.317

LT debt$M

0.335

0.303

0.307

0.332

0.331

0.358

0.345

0.387

0.389

0.347

0.784

0.93%

0.51%

8

Peers (US$1.736M)

Cap (US$)

PE

Cynata Therapeutics…

2.006M

—

Nexalis Therapeutics…

1.390M

—

Propanc Biopharma, Inc.

1.121M

—

1.697M

—

Capital

TTM

5Y

10Y

Leveragex

0.780

2.266

2.147

EBIT/Intx

3.382

0.262

0.347

Own earn%

597.34

24.79

27.89

Sh yield%

42.38

35.51

35.66

Owners

Insiders/Inst%

11.12

83.49

Short interest%

2.68

SBC / revenue%

1.30

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

1

Op margin range%

5–12

$1 testx

−0.2

Incr. ROIC%

0

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$0.571M

(0.15%)

1.00×

Cost of revenue

$0.399M

(0.15%)

1.00×

Operating expenses

$0.122M

0.11%

1.03×